Adolf Koudelka

Adolf Koudelka

Auto-generated profile, based on publicly available information

Adolf Koudelka

Masaryk University 1 Department of Biology, Faculty of Medicine Brno

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
GAGabriela Ambrožová
Gabriela Ambrožová
HMHana Martiskova
Hana Martiskova
AKAdolf Koudelka
Adolf Koudelka
TRThorben Ravekes
Thorben Ravekes
TRTanja K. Rudolph
Tanja K. Rudolph
MPMichaela Pekarova
Michaela Pekarova

1 November 2016 in Biochimica et Biophysica Acta (BBA) - General Subjects
Verified
Journal Article
Closed access
GAGabriela Ambrožová
Gabriela Ambrožová
TFTana Fidlerova
Tana Fidlerova
HVHana Verescakova
Hana Verescakova
AKAdolf Koudelka
Adolf Koudelka
TRTanja K. Rudolph
Tanja K. Rudolph
MPMichaela Pekarova
Michaela Pekarova

29 December 2021 in Redox Biology
Verified
Journal Article
Open access
AKAdolf Koudelka
Adolf Koudelka
VCVeronika Cechova
Veronika Cechova
MRMauricio Rojas
Mauricio Rojas
Nilay MitashNilay Mitash
Nilay Mitash
ABAnna Bondonese
Anna Bondonese
BFBruce Freeman
Bruce Freeman
Tissue fibrosis occurs in response to dysregulated metabolism, pro-inflammatory signaling and tissue repair reactions. For example, lungs exposed to environmental toxins, cancer therapies, chronic inflammation and other stimuli manifest a phenotypic shift to activated myofibroblasts and progressive and often irreversible lung tissue scarring. There are no therapies that stop or reverse fibrosis. The 2 FDA-approved anti-fibrotic drugs at best only slow the progression of fibrosis in humans. The present study was designed to test whether a small molecule electrophilic nitroalkene, nitro-oleic acid (NO2-OA), could reverse established pulmonary fibrosis induced by the intratracheal administration of bleomycin in C57BL/6 mice. After 14 d of bleomycin-induced fibrosis development in vivo, lungs were removed, sectioned and precision-cut lung slices (PCLS) from control and bleomycin-treated mice were cultured ex vivo for 4 d with either vehicle or NO2-OA (5 μM). Biochemical and morphological analyses showed that over a 4 d time frame, NO2-OA significantly inhibited pro-inflammatory mediator and growth factor expression and reversed key indices of fibrosis (hydroxyproline, collagen 1A1 and 3A1, fibronectin-1). Quantitative image analysis of PCLS immunohistology reinforced these observations, revealing that NO2-OA suppressed additional hallmarks of the fibrotic response, including alveolar epithelial cell loss, myofibroblast differentiation and proliferation, collagen and α-smooth muscle actin expression. NO2-OA also accelerated collagen degradation by resident macrophages. These effects occurred in the absence of the recognized NO2-OA modulation of circulating and migrating immune cell activation. Thus, small molecule nitroalkenes may be useful agents for reversing pathogenic fibrosis of lung and other organs.


17 November 2016 in Cardiovascular Drugs and Therapy
Verified
Journal Article
Closed access
PDF file
AKAdolf Koudelka
Adolf Koudelka
GAGabriela Ambrožová
Gabriela Ambrožová
AKAnna Klinke
Anna Klinke
TFTana Fidlerova
Tana Fidlerova
HMHana Martiskova
Hana Martiskova
MPMichaela Pekarova
Michaela Pekarova

1 March 2017 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
HVHana Verescakova
Hana Verescakova
GAGabriela Ambrožová
Gabriela Ambrožová
Lukas KubalaLukas Kubala
Lukas Kubala
TPTomas Perecko
Tomas Perecko
AKAdolf Koudelka
Adolf Koudelka
MPMichaela Pekarova
Michaela Pekarova